In this era of two highly effective treatment classes for patients whose tumours possess a BRAF V600 mutation, we are also faced with a lack of prospective evidence to inform our sequencing strategy, despite retrospective data to suggest that survival is favoured when immune checkpoint regimens are delivered prior to BRAF/MEK-targeted therapy.11 Whilst the glass is half-full for the outcome of many patients, we need to continue striving to meet the same standard for the rest. This evidence concerns the gene BRAF and neoplasm.